Exemestane (BioDeep_00000397578)

Main id: BioDeep_00000002169

 

natural product


代谢物信息卡片


Exemestane

化学式: C20H24O2 (296.1776)
中文名称: 依西美坦
谱图信息: 最多检出来源 Homo sapiens(urine) 6.5%

分子结构信息

SMILES: C1(C=C[C@@]2([C@@]3(CC[C@]4(C(CC[C@@]([C@](CC(C(=C1)2)=C)3[H])4[H])=O)C)[H])C)=O
InChI: InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3

描述信息

L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BG - Aromatase inhibitors
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D047072 - Aromatase Inhibitors
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
D000970 - Antineoplastic Agents
CONFIDENCE standard compound; INTERNAL_ID 2242
CONFIDENCE standard compound; INTERNAL_ID 8738

同义名列表

2 个代谢物同义名

Exemestane; Exemestane



数据库引用编号

33 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 14 AKT1, AR, BCL2, BGLAP, CDK4, EGFR, ERBB2, ESR1, MTOR, PGR, PIK3C3, PIK3CA, PTGS2, TP53
Peripheral membrane protein 4 CYP1B1, ESR1, MTOR, PTGS2
Endosome membrane 2 EGFR, ERBB2
Endoplasmic reticulum membrane 6 BCL2, CYP19A1, CYP1B1, EGFR, MTOR, PTGS2
Cytoplasmic vesicle, autophagosome 1 PIK3C3
Nucleus 11 AKT1, AR, BCL2, CDK4, EGFR, ERBB2, ESR1, MKI67, MTOR, PGR, TP53
autophagosome 1 PIK3C3
cytosol 12 AKT1, AR, BCL2, CDK4, ERBB2, ESR1, GPT, MTOR, PGR, PIK3C3, PIK3CA, TP53
dendrite 2 BGLAP, MTOR
nuclear body 1 MKI67
phagocytic vesicle 1 MTOR
phosphatidylinositol 3-kinase complex, class III 1 PIK3C3
centrosome 1 TP53
nucleoplasm 9 AKT1, AR, CDK4, ERBB2, ESR1, MKI67, MTOR, PGR, TP53
Cell membrane 4 AKT1, EGFR, ERBB2, ESR1
Cytoplasmic side 2 ESR1, MTOR
lamellipodium 2 AKT1, PIK3CA
ruffle membrane 2 EGFR, ERBB2
Early endosome membrane 1 EGFR
Multi-pass membrane protein 1 CYP19A1
Golgi apparatus membrane 1 MTOR
cell cortex 1 AKT1
cell junction 1 EGFR
cell surface 1 EGFR
glutamatergic synapse 3 AKT1, EGFR, PIK3C3
Golgi apparatus 1 ESR1
Golgi membrane 2 EGFR, MTOR
lysosomal membrane 2 EGF, MTOR
neuromuscular junction 1 ERBB2
postsynapse 1 AKT1
presynaptic membrane 1 ERBB2
Lysosome 1 MTOR
endosome 2 EGFR, PIK3C3
plasma membrane 8 AKT1, AR, EGF, EGFR, ERBB2, ESR1, PGR, PIK3CA
Membrane 13 AKT1, AR, BCL2, CYP19A1, CYP1B1, EGF, EGFR, ERBB2, ESR1, MKI67, MTOR, PIK3C3, TP53
apical plasma membrane 2 EGFR, ERBB2
basolateral plasma membrane 2 EGFR, ERBB2
caveola 1 PTGS2
extracellular exosome 2 EGF, GPT
Lysosome membrane 1 MTOR
endoplasmic reticulum 4 BCL2, CYP19A1, PTGS2, TP53
extracellular space 4 BGLAP, EGF, EGFR, XCL1
perinuclear region of cytoplasm 3 EGFR, ERBB2, PIK3CA
bicellular tight junction 1 CDK4
intercalated disc 1 PIK3CA
mitochondrion 3 BCL2, CYP1B1, TP53
protein-containing complex 7 AKT1, AR, BCL2, EGFR, ESR1, PTGS2, TP53
intracellular membrane-bounded organelle 1 CYP1B1
Microsome membrane 4 CYP19A1, CYP1B1, MTOR, PTGS2
TORC1 complex 1 MTOR
TORC2 complex 1 MTOR
Single-pass type I membrane protein 2 EGFR, ERBB2
Secreted 1 BGLAP
extracellular region 4 BGLAP, EGF, ERBB2, XCL1
Mitochondrion outer membrane 2 BCL2, MTOR
Single-pass membrane protein 1 BCL2
mitochondrial outer membrane 3 BCL2, MTOR, PGR
Mitochondrion matrix 1 TP53
mitochondrial matrix 1 TP53
transcription regulator complex 3 CDK4, ESR1, TP53
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 1 TP53
Nucleus membrane 2 BCL2, CDK4
Bcl-2 family protein complex 1 BCL2
nuclear membrane 3 BCL2, CDK4, EGFR
perikaryon 1 BGLAP
cytoplasmic vesicle 1 ERBB2
microtubule cytoskeleton 1 AKT1
nucleolus 3 CDK4, MKI67, TP53
midbody 1 PIK3C3
Early endosome 1 ERBB2
cell-cell junction 1 AKT1
vesicle 2 AKT1, BGLAP
Cell projection, ruffle membrane 1 ERBB2
Cytoplasm, perinuclear region 1 ERBB2
Membrane raft 1 EGFR
pore complex 1 BCL2
Cytoplasm, cytoskeleton 1 TP53
focal adhesion 1 EGFR
spindle 1 AKT1
GABA-ergic synapse 1 PIK3C3
Peroxisome 1 PIK3C3
intracellular vesicle 1 EGFR
Nucleus, PML body 2 MTOR, TP53
PML body 2 MTOR, TP53
Mitochondrion intermembrane space 1 AKT1
mitochondrial intermembrane space 1 AKT1
axoneme 1 PIK3C3
nuclear speck 1 AR
Nucleus inner membrane 1 PTGS2
Nucleus outer membrane 1 PTGS2
nuclear inner membrane 1 PTGS2
nuclear outer membrane 1 PTGS2
Late endosome 1 PIK3C3
receptor complex 2 EGFR, ERBB2
neuron projection 1 PTGS2
ciliary basal body 1 AKT1
chromatin 5 AR, CDK4, ESR1, PGR, TP53
phagocytic vesicle membrane 1 PIK3C3
Chromosome 1 MKI67
Nucleus, nucleolus 1 MKI67
site of double-strand break 1 TP53
nuclear envelope 1 MTOR
Endomembrane system 1 MTOR
phagophore assembly site 1 PIK3C3
phosphatidylinositol 3-kinase complex, class III, type I 1 PIK3C3
phosphatidylinositol 3-kinase complex, class III, type II 1 PIK3C3
euchromatin 1 ESR1
germ cell nucleus 1 TP53
replication fork 1 TP53
myelin sheath 2 BCL2, ERBB2
basal plasma membrane 2 EGFR, ERBB2
synaptic membrane 1 EGFR
Golgi lumen 1 BGLAP
endoplasmic reticulum lumen 2 BGLAP, PTGS2
nuclear matrix 1 TP53
transcription repressor complex 1 TP53
platelet alpha granule lumen 1 EGF
phosphatidylinositol 3-kinase complex 1 PIK3CA
phosphatidylinositol 3-kinase complex, class IA 1 PIK3CA
presynaptic endosome 1 PIK3C3
semaphorin receptor complex 1 ERBB2
clathrin-coated endocytic vesicle membrane 2 EGF, EGFR
[Isoform 1]: Nucleus 2 ESR1, TP53
[Isoform 1]: Cell membrane 1 ERBB2
Cytoplasmic vesicle, phagosome 1 MTOR
cyclin-dependent protein kinase holoenzyme complex 1 CDK4
postsynaptic endosome 1 PIK3C3
multivesicular body, internal vesicle lumen 1 EGFR
Shc-EGFR complex 1 EGFR
Autolysosome 1 PIK3C3
ERBB3:ERBB2 complex 1 ERBB2
[Isoform 4]: Mitochondrion outer membrane 1 PGR
BAD-BCL-2 complex 1 BCL2
cyclin D1-CDK4 complex 1 CDK4
cyclin D2-CDK4 complex 1 CDK4
cyclin D3-CDK4 complex 1 CDK4
phosphatidylinositol 3-kinase complex, class IB 1 PIK3CA


文献列表

  • LiJun Yang, Yuan Xiang, SiQi Wu, Mihnea-Alexandru Găman, Kousalya Prabahar, ZhaoXia Chen. The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomized controlled trials. European journal of obstetrics, gynecology, and reproductive biology. 2024 Apr; 295(?):25-33. doi: 10.1016/j.ejogrb.2024.01.021. [PMID: 38325240]
  • Md Rizwanullah, Ahmad Perwez, Meraj Alam, Shahnawaz Ahmad, Showkat Rasool Mir, Mohd Moshahid Alam Rizvi, Saima Amin. Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation. International journal of pharmaceutics. 2023 Jun; 642(?):123136. doi: 10.1016/j.ijpharm.2023.123136. [PMID: 37311498]
  • Priya Singh, Alka, Priyanka Maurya, Raquibun Nisha, Neelu Singh, Poonam Parashar, Nidhi Mishra, Ravi Raj Pal, Shubhini A Saraf. QbD-assisted development of lipidic nanocapsules for antiestrogenic activity of exemestane in breast cancer. Journal of liposome research. 2023 Jun; 33(2):154-169. doi: 10.1080/08982104.2022.2108441. [PMID: 35930249]
  • Jiayu Wang, Li Cai, Yanqiu Song, Tao Sun, Zhongsheng Tong, Yuee Teng, Huiping Li, Quchang Ouyang, Qianjun Chen, Shude Cui, Yongmei Yin, Ning Liao, Qiang Sun, Jifeng Feng, Xiaojia Wang, Binghe Xu. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). European journal of cancer (Oxford, England : 1990). 2023 Feb; 184(?):73-82. doi: 10.1016/j.ejca.2023.02.007. [PMID: 36905771]
  • Irina Teslenko, Christy J W Watson, Zuping Xia, Gang Chen, Philip Lazarus. Characterization of Cytosolic Glutathione S-Transferases Involved in the Metabolism of the Aromatase Inhibitor, Exemestane. Drug metabolism and disposition: the biological fate of chemicals. 2021 12; 49(12):1047-1055. doi: 10.1124/dmd.121.000635. [PMID: 34593616]
  • Norikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, Akihiko Shimomura, Masataka Sawaki, Min-Jung Lee, Akira Yuno, Jane Trepel, Ryoko Kimura, Yozo Nishimura, Shigehira Saji, Hiroji Iwata. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. BMC cancer. 2021 Nov; 21(1):1269. doi: 10.1186/s12885-021-08973-4. [PMID: 34819039]
  • Aliana Guerrieri-Gonzaga, Davide Serrano, Parjhitham Thomas, Katherine D Crew, Nagi B Kumar, Sara Gandini, Lana A Vornik, Jack Lee, Sara Cagnacci, Elisa Vicini, Chiara A Accornero, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Tania B Webber, Powel H Brown, Eva Szabo, Brandy Heckman-Stoddard, Bernardo Bonanni. Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial. Contemporary clinical trials. 2021 08; 107(?):106498. doi: 10.1016/j.cct.2021.106498. [PMID: 34216815]
  • Md Rizwanullah, Ahmad Perwez, Showkat Rasool Mir, Mohd Moshahid Alam Rizvi, Saima Amin. Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization,in vitrocharacterization and cell culture studies. Nanotechnology. 2021 Jul; 32(41):. doi: 10.1088/1361-6528/ac1098. [PMID: 34198267]
  • Giuseppe Curigliano, Miguel Martin, Komal Jhaveri, J T Beck, Giampaolo Tortora, Nicola Fazio, Michela Maur, Richard A Hubner, Harald Lahner, Valerie Donnet, Olga Ajipa, Zheng Li, Lars Blumenstein, Fabrice Andre. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European journal of cancer (Oxford, England : 1990). 2021 07; 151(?):49-62. doi: 10.1016/j.ejca.2021.03.042. [PMID: 33964572]
  • I Narang, A P Panthagani, M Lewis, B Chohan, A Ferguson, R Nambi. COVID-19-induced toxic epidermal necrolysis. Clinical and experimental dermatology. 2021 07; 46(5):927-929. doi: 10.1111/ced.14574. [PMID: 33511662]
  • Nicholas C Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U Budzar, John F R Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M Bliss, Mitch Dowsett, Stephen R D Johnston, Stephen K Chia. ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 10; 26(19):5172-5177. doi: 10.1158/1078-0432.ccr-20-0224. [PMID: 32546646]
  • Shailima Rampogu, Seong Min Kim, Minky Son, Ayoung Baek, Chanin Park, Gihwan Lee, Yumi Kim, Gon Sup Kim, Ju Hyun Kim, Keun Woo Lee. A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines. Biomolecules. 2020 06; 10(6):. doi: 10.3390/biom10060857. [PMID: 32512851]
  • Nazli Bahrami, Gregory Chang, Noriko Kanaya, Torill Sauer, Daehoon Park, Marie Loeng, Berit Gravdehaug, Shiuan Chen, Jürgen Geisler. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. The Journal of steroid biochemistry and molecular biology. 2020 06; 200(?):105641. doi: 10.1016/j.jsbmb.2020.105641. [PMID: 32151708]
  • Dinja T Kruger, Maurice P H M Jansen, Inge R H M Konings, Wouter M Dercksen, Agnes Jager, Jamal Oulad Hadj, Stefan Sleijfer, John W M Martens, Epie Boven. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. Molecular oncology. 2020 03; 14(3):490-503. doi: 10.1002/1878-0261.12617. [PMID: 31841262]
  • Allison P Garcia, Jacob B Hatvany, Michael A Murphy, Daniel H Atchley, Bill J Gurley, Landry K Kamdem. Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women. Journal of clinical pharmacology. 2020 02; 60(2):209-217. doi: 10.1002/jcph.1519. [PMID: 31535401]
  • Tao He, Wenhao Yang, Xinyi Zhang, Ping Li, Dandan Yang, Yunhao Wu, Yuan Fan, Mengya Xiang, Qianqian Huang, Jing Chen, Runke Zhou, Qing Lv, Jie Chen. Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Medicine. 2020 Jan; 99(2):e18550. doi: 10.1097/md.0000000000018550. [PMID: 31914031]
  • Mohamed Gaber, Mark Hany, Sarah Mokhtar, Maged W Helmy, Kadria A Elkodairy, Ahmed O Elzoghby. Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. Materials science & engineering. C, Materials for biological applications. 2019 Dec; 105(?):110099. doi: 10.1016/j.msec.2019.110099. [PMID: 31546395]
  • Fengqin Wei, Weiyu Chen, Xiaoti Lin. Efficacy and safety of adjuvant endocrine therapy in premenopausal patients with early-stage hormone receptor-positive breast cancer: A meta-analysis of randomized controlled trials. The breast journal. 2019 11; 25(6):1297-1299. doi: 10.1111/tbj.13465. [PMID: 31301082]
  • Archu Singh, Yub Raj Neupane, Bharti Mangla, Kanchan Kohli. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies. Journal of pharmaceutical sciences. 2019 10; 108(10):3382-3395. doi: 10.1016/j.xphs.2019.06.003. [PMID: 31201904]
  • Annelieke E C A B Willemsen, Jolien Tol, Nielka P van Erp, Marianne A Jonker, Maaike de Boer, Bob Meek, Paul C de Jong, Coline van Moorsel, Winald R Gerritsen, Jan C Grutters, Carla M L van Herpen. Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Targeted oncology. 2019 08; 14(4):441-451. doi: 10.1007/s11523-019-00656-2. [PMID: 31325105]
  • Amelia McCartney, Chiara Biagioni, Gaia Schiavon, Mattias Bergqvist, Karin Mattsson, Ilenia Migliaccio, Matteo Benelli, Dario Romagnoli, Martina Bonechi, Giulia Boccalini, Marta Pestrin, Francesca Galardi, Francesca De Luca, Laura Biganzoli, Martine Piccart, William J Gradishar, Stephen Chia, Angelo Di Leo, Luca Malorni. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European journal of cancer (Oxford, England : 1990). 2019 06; 114(?):55-66. doi: 10.1016/j.ejca.2019.04.002. [PMID: 31059974]
  • Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Yueyin Pan, Yuping Sun, Hong Wang, Tao Ouyang, Kangsheng Gu, Jifeng Feng, Xiaojia Wang, Shubin Wang, Tianshu Liu, Jinghua Gao, Massimo Cristofanilli, Zhiqiang Ning, Xianping Lu. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2019 06; 20(6):806-815. doi: 10.1016/s1470-2045(19)30164-0. [PMID: 31036468]
  • Jacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, Andrea M Pesch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F Hayes, N Lynn Henry, James M Rae, Daniel L Hertz. Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics. 2019 06; 20(8):571-580. doi: 10.2217/pgs-2019-0020. [PMID: 31190621]
  • M van Nuland, N Venekamp, N de Vries, K A M de Jong, H Rosing, J H Beijnen. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2019 Feb; 1106-1107(?):26-34. doi: 10.1016/j.jchromb.2019.01.001. [PMID: 30639947]
  • Wesley J Goedegebuure, Anita C S Hokken-Koelega. Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report. Hormone research in paediatrics. 2019; 92(3):209-213. doi: 10.1159/000501746. [PMID: 31390647]
  • Shaman Luo, Gang Chen, Cristina I Truica, Cynthia C Baird, Zuping Xia, Philip Lazarus. Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane. Drug metabolism and disposition: the biological fate of chemicals. 2018 12; 46(12):1867-1878. doi: 10.1124/dmd.118.081166. [PMID: 30257855]
  • Wei Tian, Miaowei Wu, Yongchuan Deng. Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study. Clinical pharmacology in drug development. 2018 11; 7(8):837-843. doi: 10.1002/cpdd.420. [PMID: 29287126]
  • Ali Nazaripour, Yadollah Yamini, Hasan Bagheri. Extraction and determination of trace amounts of three anticancer pharmaceuticals in urine by three-phase hollow fiber liquid-phase microextraction based on two immiscible organic solvents followed by high-performance liquid chromatography. Journal of separation science. 2018 Aug; 41(15):3113-3120. doi: 10.1002/jssc.201800183. [PMID: 29869408]
  • S Luo, G Chen, C Truica, C C Baird, K Leitzel, P Lazarus. Role of the UGT2B17 deletion in exemestane pharmacogenetics. The pharmacogenomics journal. 2018 04; 18(2):295-300. doi: 10.1038/tpj.2017.18. [PMID: 28534527]
  • Sophia Mastoraki, Areti Strati, Eleni Tzanikou, Maria Chimonidou, Eleni Politaki, Alexandra Voutsina, Amanda Psyrri, Vassilis Georgoulias, Evi Lianidou. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 03; 24(6):1500-1510. doi: 10.1158/1078-0432.ccr-17-1181. [PMID: 29284708]
  • Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, Sandeep K Agarwal, Robert L Welschhans, Tim Bongartz, Krishna R Kalari, Lois E Shepherd, John Bartlett, Kathleen Pritchard, Karen Gelmon, Susan G Hilsenbeck, Mothaffar F Rimawi, C Kent Osborne, Paul E Goss, James N Ingle. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clinical breast cancer. 2018 02; 18(1):78-87. doi: 10.1016/j.clbc.2017.10.009. [PMID: 29128193]
  • B J Gregory, S M Chen, M A Murphy, D H Atchley, L K Kamdem. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. Journal of clinical pharmacy and therapeutics. 2017 Oct; 42(5):547-553. doi: 10.1111/jcpt.12569. [PMID: 28868654]
  • Brandi L Clark, Michael A Murphy, Landry K Kamdem. COX2 induction: a mechanism of endocrine breast cancer resistance?. Breast cancer research and treatment. 2017 Sep; 165(2):383-389. doi: 10.1007/s10549-017-4284-7. [PMID: 28639029]
  • Basanth Babu Eedara, Suresh Bandari. Lipid-based dispersions of exemestane for improved dissolution rate and intestinal permeability: in vitro and ex vivo characterization. Artificial cells, nanomedicine, and biotechnology. 2017 Aug; 45(5):917-927. doi: 10.1080/21691401.2016.1193023. [PMID: 27267814]
  • Florence Dalenc, Luiggi Iuliano, Thomas Filleron, Chiara Zerbinati, Maud Voisin, Cécile Arellano, Etienne Chatelut, Pierre Marquet, Mohammad Samadi, Henri Roché, Marc Poirot, Sandrine Silvente-Poirot. Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. The Journal of steroid biochemistry and molecular biology. 2017 05; 169(?):210-218. doi: 10.1016/j.jsbmb.2016.06.010. [PMID: 27343991]
  • Mary Ellen Moynahan, David Chen, Wei He, Patricia Sung, Aliaksandra Samoila, Daoqi You, Trusha Bhatt, Parul Patel, Francois Ringeisen, Gabriel N Hortobagyi, Jose Baselga, Sarat Chandarlapaty. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2. British journal of cancer. 2017 Mar; 116(6):726-730. doi: 10.1038/bjc.2017.25. [PMID: 28183140]
  • Jason D Robarge, Zereunesay Desta, Anne T Nguyen, Lang Li, Daniel Hertz, James M Rae, Daniel F Hayes, Anna M Storniolo, Vered Stearns, David A Flockhart, Todd C Skaar, N Lynn Henry. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast cancer research and treatment. 2017 02; 161(3):453-461. doi: 10.1007/s10549-016-4077-4. [PMID: 27943008]
  • Weimin Li, Joyce O'Shaughnessy, Daniel Hayes, Mario Campone, Igor Bondarenko, Irina Zbarskaya, Etienne Brain, Marina Stenina, Olga Ivanova, Marie-Pascale Graas, Patrick Neven, Deborah Ricci, Thomas Griffin, Thian Kheoh, Margaret Yu, Michael Gormley, Jason Martin, Michael Schaffer, Kathy Zelinsky, Peter De Porre, Stephen R D Johnston. Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Dec; 22(24):6002-6009. doi: 10.1158/1078-0432.ccr-15-2452. [PMID: 27267854]
  • Charlotte Fribbens, Ben O'Leary, Lucy Kilburn, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Massimo Cristofanilli, Fabrice Andre, Sherene Loi, Sibylle Loibl, John Jiang, Cynthia Huang Bartlett, Maria Koehler, Mitch Dowsett, Judith M Bliss, Stephen R D Johnston, Nicholas C Turner. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 09; 34(25):2961-8. doi: 10.1200/jco.2016.67.3061. [PMID: 27269946]
  • Shanly M Chen, Daniel H Atchley, Michael A Murphy, Bill J Gurley, Landry K Kamdem. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers. Journal of clinical pharmacology. 2016 07; 56(7):875-84. doi: 10.1002/jcph.673. [PMID: 26608382]
  • Margaret E Gatti-Mays, David Venzon, Claudia E Galbo, Andrea Singer, James Reynolds, Erini Makariou, Bhaskar Kallakury, Brandy M Heckman-Stoddard, Larissa Korde, Claudine Isaacs, Robert Warren, Ann Gallagher, Jennifer Eng-Wong. Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer prevention research (Philadelphia, Pa.). 2016 Mar; 9(3):225-33. doi: 10.1158/1940-6207.capr-15-0269. [PMID: 26758879]
  • Aurélien Saltel-Fulero, Anne Donnadieu, Solenne Leman-Detours, Paul Cottu. [New options in adjuvant endocrine therapy in breast cancer]. Bulletin du cancer. 2016 Jan; 103(1):104-12. doi: 10.1016/j.bulcan.2015.10.011. [PMID: 26675809]
  • Steffi Oesterreich, N Lynn Henry, Kelley M Kidwell, Catherine H Van Poznak, Todd C Skaar, Jessica Dantzer, Lang Li, Thomas N Hangartner, Munro Peacock, Anne T Nguyen, James M Rae, Zeruesenay Desta, Santosh Philips, Anna M Storniolo, Vered Stearns, Daniel F Hayes, David A Flockhart. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast cancer research and treatment. 2015 Nov; 154(2):263-73. doi: 10.1007/s10549-015-3608-8. [PMID: 26536870]
  • Ling-Zhi Wang, Sok-Hwei Goh, Andrea Li-Ann Wong, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Soo-Chin Lee, Paul C Ho, Boon-Cher Goh. Validation of a rapid and sensitive LC-MS/MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: application to human pharmacokinetics study. PloS one. 2015; 10(3):e0118553. doi: 10.1371/journal.pone.0118553. [PMID: 25793887]
  • Francesca Donders, Dirk Kuypers, Pascal Wolter, Patrick Neven. Everolimus in acute kidney injury in a patient with breast cancer: a case report. Journal of medical case reports. 2014 Nov; 8(?):386. doi: 10.1186/1752-1947-8-386. [PMID: 25420955]
  • Mohan Liu, Paul E Goss, James N Ingle, Michiaki Kubo, Yoichi Furukawa, Anthony Batzler, Gregory D Jenkins, Erin E Carlson, Yusuke Nakamura, Daniel J Schaid, Judy-Anne W Chapman, Lois E Shepherd, Matthew J Ellis, Sundeep Khosla, Liewei Wang, Richard M Weinshilboum. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Molecular endocrinology (Baltimore, Md.). 2014 Oct; 28(10):1740-51. doi: 10.1210/me.2014-1147. [PMID: 25148458]
  • Yuli Zhao, Jessica M Boyd, Michael B Sawyer, Xing-Fang Li. Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment. Analytica chimica acta. 2014 Jan; 806(?):172-9. doi: 10.1016/j.aca.2013.11.014. [PMID: 24331053]
  • Francisco J Esteva, Stacy L Moulder, Ana M Gonzalez-Angulo, Joe Ensor, James L Murray, Marjorie C Green, Kimberly B Koenig, Mong-Hong Lee, Gabriel N Hortobagyi, Sai-Ching Yeung. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer chemotherapy and pharmacology. 2013 Jan; 71(1):63-72. doi: 10.1007/s00280-012-1977-9. [PMID: 23053261]
  • Lauren Nicole Bell, Anne Thi Phuong Nguyen, Lang Li, Zeruesenay Desta, N Lynn Henry, Daniel F Hayes, Antonio C Wolff, Vered Stearns, Anna Maria Storniolo, David A Flockhart. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. Journal of clinical pharmacology. 2012 Dec; 52(12):1852-60. doi: 10.1177/0091270011424153. [PMID: 22174434]
  • P Hadji, A Kauka, T Bauer, J Tams, A Hasenburg, D G Kieback. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric : the journal of the International Menopause Society. 2012 Oct; 15(5):460-6. doi: 10.3109/13697137.2011.647839. [PMID: 22321061]
  • Xiomara Rocha-Cadman, Mary Jane Massie, Katherine Du Hamel. Aromatase inhibitors and mood disturbances. Palliative & supportive care. 2012 Sep; 10(3):225-7. doi: 10.1017/s1478951512000636. [PMID: 22677000]
  • Tao Xu, Nian-Song Wang, Li-Li Fu, Chao-Yang Ye, Sheng-Qiang Yu, Chang-Lin Mei. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Molecular biology reports. 2012 Jul; 39(7):7743-53. doi: 10.1007/s11033-012-1611-2. [PMID: 22415852]
  • J S McLay, D Stewart, J George, C Rore, S D Heys. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions?. European journal of clinical pharmacology. 2012 May; 68(5):811-9. doi: 10.1007/s00228-011-1181-6. [PMID: 22166933]
  • Ewa Mrózek, Rachel Layman, Bhuvaneswari Ramaswamy, Larry Schaaf, Xiaobai Li, Susan Ottman, Charles L Shapiro. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. Clinical breast cancer. 2012 Apr; 12(2):151-6. doi: 10.1016/j.clbc.2012.01.003. [PMID: 22444722]
  • Kristin Dickschen, Stefan Willmann, Kirstin Thelen, Jörg Lippert, Georg Hempel, Thomas Eissing. Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance. Frontiers in pharmacology. 2012; 3(?):92. doi: 10.3389/fphar.2012.00092. [PMID: 22661948]
  • Wenhua Jiang, Debashis Ghosh. Motion and flexibility in human cytochrome p450 aromatase. PloS one. 2012; 7(2):e32565. doi: 10.1371/journal.pone.0032565. [PMID: 22384274]
  • Muhammad Younus, Michelle Kissner, Lester Reich, Nicola Wallis. Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature. Drug safety. 2011 Dec; 34(12):1125-49. doi: 10.2165/11594170-000000000-00000. [PMID: 22077502]
  • Z Desta, Y Kreutz, A T Nguyen, L Li, T Skaar, L K Kamdem, N L Henry, D F Hayes, A M Storniolo, V Stearns, E Hoffmann, R F Tyndale, D A Flockhart. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clinical pharmacology and therapeutics. 2011 Nov; 90(5):693-700. doi: 10.1038/clpt.2011.174. [PMID: 21975350]
  • Gustavo de Albuquerque Cavalcanti, Bruno Carius Garrido, Felipe Dias Leal, Monica Costa Padilha, Monica Mazzarino, Xavier de la Torre, Francesco Botre, Francisco Radler de Aquino Neto. Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry. The Journal of steroid biochemistry and molecular biology. 2011 Nov; 127(3-5):248-54. doi: 10.1016/j.jsbmb.2011.08.014. [PMID: 21924357]
  • Gustavo de Albuquerque Cavalcanti, Bruno Carius Garrido, Felipe Dias Leal, Monica Costa Padilha, Xavier de la Torre, Francisco Radler de Aquino Neto. Detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry. Steroids. 2011 Sep; 76(10-11):1010-5. doi: 10.1016/j.steroids.2011.04.001. [PMID: 21530565]
  • Federica Tomao, Gianpaolo Spinelli, Patrizia Vici, Giovanni Codacci Pisanelli, Gianluca Cascialli, Luigi Frati, Pierluigi Benedetti Panici, Silverio Tomao. Current role and safety profile of aromatase inhibitors in early breast cancer. Expert review of anticancer therapy. 2011 Aug; 11(8):1253-63. doi: 10.1586/era.11.96. [PMID: 21916579]
  • Gregg D Cappon, Robert E Chapin, Mark E Hurtt, Michael P Wajnrajch, Leigh Ann Burns-Naas. Impaired reproduction in adult male, but not female, rats following juvenile treatment with the aromatase inhibitor, exemestane. Birth defects research. Part B, Developmental and reproductive toxicology. 2011 Aug; 92(4):304-13. doi: 10.1002/bdrb.20307. [PMID: 21678547]
  • Y Hozumi, K Suemasu, H Takei, T Aihara, M Takehara, T Saito, S Ohsumi, N Masuda, Y Ohashi. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Aug; 22(8):1777-82. doi: 10.1093/annonc/mdq707. [PMID: 21285133]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Hanna Ksycińska, Katarzyna Buś-Kwaśnik, Anna Szlagowska, Piotr J Rudzki. Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2011 Jul; 879(21):1905-10. doi: 10.1016/j.jchromb.2011.05.015. [PMID: 21641878]
  • T Cigler, H Richardson, M J Yaffe, C J Fabian, D Johnston, J N Ingle, E Nassif, R L Brunner, M E Wood, J L Pater, H Hu, S Qi, D Tu, P E Goss. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast cancer research and treatment. 2011 Apr; 126(2):453-61. doi: 10.1007/s10549-010-1322-0. [PMID: 21221773]
  • P E Lønning. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Mar; 22(3):503-514. doi: 10.1093/annonc/mdq337. [PMID: 20616198]
  • Nermine K Saleh, Hanan A Saleh. Olive oil effectively mitigates ovariectomy-induced osteoporosis in rats. BMC complementary and alternative medicine. 2011 Feb; 11(?):10. doi: 10.1186/1472-6882-11-10. [PMID: 21294895]
  • Yasuhisa Kobayashi, Ryo Nozu, Masaru Nakamura. Role of estrogen in spermatogenesis in initial phase males of the three-spot wrasse (Halichoeres trimaculatus): effect of aromatase inhibitor on the testis. Developmental dynamics : an official publication of the American Association of Anatomists. 2011 Jan; 240(1):116-21. doi: 10.1002/dvdy.22507. [PMID: 21117145]
  • Todd W Miller, Brent N Rexer, Joan T Garrett, Carlos L Arteaga. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast cancer research : BCR. 2011; 13(6):224. doi: 10.1186/bcr3039. [PMID: 22114931]
  • Agata Bielecka-Dąbrowa, Simon Hannam, Jacek Rysz, Maciej Banach. Malignancy-associated dyslipidemia. The open cardiovascular medicine journal. 2011; 5(?):35-40. doi: 10.2174/1874192401105010035. [PMID: 21660223]
  • Gustavo de A Cavalcanti, Bruno C Garrido, Felipe D Leal, Monica C Padilha, Xavier de la Torre, Henrique M G Pereira, Francisco R de Aquino Neto. Analysis of exemestane and 17β-hydroxyexemestane in human urine by gas chromatography/mass spectrometry: development and validation of a method using MO-TMS derivatives. Rapid communications in mass spectrometry : RCM. 2010 Nov; 24(22):3297-302. doi: 10.1002/rcm.4779. [PMID: 20973004]
  • N L Henry, D Pchejetski, R A'Hern, A T Nguyen, P Charles, J Waxman, L Li, A M Storniolo, D F Hayes, D A Flockhart, V Stearns, J Stebbing. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. British journal of cancer. 2010 Jul; 103(3):291-6. doi: 10.1038/sj.bjc.6605768. [PMID: 20606683]
  • Xavier Nogues, Sonia Servitja, Maria Jesus Peña, Daniel Prieto-Alhambra, Rosa Nadal, Leonardo Mellibovsky, Joan Albanell, Adolfo Diez-Perez, Ignasi Tusquets. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas. 2010 Jul; 66(3):291-7. doi: 10.1016/j.maturitas.2010.03.012. [PMID: 20399042]
  • Sabina Ruksana, Narayan P Pandit, Masaru Nakamura. Efficacy of exemestane, a new generation of aromatase inhibitor, on sex differentiation in a gonochoristic fish. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. 2010 Jun; 152(1):69-74. doi: 10.1016/j.cbpc.2010.02.014. [PMID: 20193775]
  • J Doyen, A Italiano, R Largillier, J-M Ferrero, X Fontana, A Thyss. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Jun; 21(6):1243-1245. doi: 10.1093/annonc/mdp450. [PMID: 19861576]
  • Giacomo Corrado, Giorgia Garganese, Gilda Fuoco, Arnaldo Carbone, Giovanni Scambia, Gabriella Ferrandina. Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report. Diagnostic pathology. 2010 May; 5(?):29. doi: 10.1186/1746-1596-5-29. [PMID: 20478044]
  • Wolfgang Janni, Philip Hepp. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer treatment reviews. 2010 May; 36(3):249-61. doi: 10.1016/j.ctrv.2009.12.010. [PMID: 20133065]
  • P E Lønning, J Geisler. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?. The Journal of steroid biochemistry and molecular biology. 2010 Feb; 118(4-5):288-93. doi: 10.1016/j.jsbmb.2009.09.013. [PMID: 19808096]
  • T Aihara, K Suemasu, H Takei, Y Hozumi, M Takehara, T Saito, S Ohsumi, N Masuda, Y Ohashi. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology. 2010; 79(5-6):376-81. doi: 10.1159/000323489. [PMID: 21430407]
  • O C Freedman, E Amir, W Hanna, H Kahn, F O'Malley, G Dranitsaris, D E C Cole, S Verma, E Folkerd, M Dowsett, M Clemons. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast cancer research and treatment. 2010 Jan; 119(1):155-61. doi: 10.1007/s10549-009-0523-x. [PMID: 19731013]
  • Qamar J Khan, Anne P O'Dea, Priyanka Sharma. Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. Journal of oncology. 2010; 2010(?):. doi: 10.1155/2010/654348. [PMID: 20871846]
  • Gerhard Groenewoud, Andre Nell, Linda Potgieter, Dan Seiler, Christine Wettmarshausen. Bioequivalence of exemestane in post-menopausal females. Arzneimittel-Forschung. 2010; 60(2):96-100. doi: 10.1055/s-0031-1296255. [PMID: 20329658]
  • Taeko Nagao, Misako Kira, Masako Takahashi, Junko Honda, Toshiyuki Hirose, Akira Tangoku, Hitoshi Zembutsu, Yusuke Nakamura, Mitsunori Sasa. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. World journal of surgical oncology. 2009 Nov; 7(?):88. doi: 10.1186/1477-7819-7-88. [PMID: 19909552]
  • Alain Monnier. Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review. Therapeutics and clinical risk management. 2009 Oct; 5(5):725-38. doi: 10.2147/tcrm.s3858. [PMID: 19774214]
  • Praveen S Hiremath, Kumaresh S Soppimath, Guru V Betageri. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. International journal of pharmaceutics. 2009 Oct; 380(1-2):96-104. doi: 10.1016/j.ijpharm.2009.07.008. [PMID: 19616608]
  • Andrea Camerini, Marianna Rondini, Ornella Garrone, Chiara Valsuani, Sara Donati, Olimpia Siclari, Alessandro Sgambato, Gianna Tartarelli, Maura Vincenti, Valentina Polla Mattiot, Romana Prosperi Porta, Cheti Puccetti, Paolo Puccinelli, Domenico Amoroso. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer biology & therapy. 2009 Aug; 8(15):1450-5. doi: 10.4161/cbt.8.15.8959. [PMID: 19556864]
  • Giuseppe Corona, Caterina Elia, Bruno Casetta, Crivellari Diana, Sara Rosalen, Mario Bari, Giuseppe Toffoli. A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. Journal of mass spectrometry : JMS. 2009 Jun; 44(6):920-8. doi: 10.1002/jms.1566. [PMID: 19214962]
  • C Falandry, P A Canney, G Freyer, L Y Dirix. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Apr; 20(4):615-20. doi: 10.1093/annonc/mdn693. [PMID: 19254941]
  • Maria Gabriella Jannuzzo, Enrico Di Salle, Riccardo Spinelli, Nicoletta Pirotta, Peter Buchan, Akintunde Bello. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast cancer research and treatment. 2009 Feb; 113(3):491-9. doi: 10.1007/s10549-008-9949-9. [PMID: 18330698]
  • Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou, Helen Gogas. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast cancer research : BCR. 2009; 11(3):R35. doi: 10.1186/bcr2320. [PMID: 19531217]
  • C Markopoulos, A Polychronis, U Dafni, D Koukouras, V Zobolas, E Tzorakoleftherakis, G Xepapadakis, H Gogas. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Jan; 20(1):49-55. doi: 10.1093/annonc/mdn545. [PMID: 18678766]
  • A Montagnani, S Gonnelli, A Cadirni, C Caffarelli, K Del Santo, C Pieropan, M S Campagna, M Montomoli, R Petrioli, R Nuti. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. European journal of internal medicine. 2008 Dec; 19(8):592-7. doi: 10.1016/j.ejim.2007.05.016. [PMID: 19046724]
  • Yutaka Yamamoto, Hirotaka Iwase. Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. International journal of clinical oncology. 2008 Oct; 13(5):384-94. doi: 10.1007/s10147-008-0828-5. [PMID: 18946748]
  • T A Traina, I Poggesi, M Robson, A Asnis, B A Duncan, A Heerdt, C Dang, D Lake, M Moasser, K Panageas, P Borgen, L Norton, C Hudis, M N Dickler. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast cancer research and treatment. 2008 Sep; 111(2):377-88. doi: 10.1007/s10549-007-9787-1. [PMID: 17952589]
  • Peter McCormack, Francisco Sapunar. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. Clinical breast cancer. 2008 Aug; 8(4):347-51. doi: 10.3816/cbc.2008.n.040. [PMID: 18757262]
  • Lee R Jackson, Kwok L Cheung, Aman U Buzdar, John F R Robertson. Arzoxifene: the evidence for its development in the management of breast cancer. Core evidence. 2008 Jul; 2(4):251-8. doi: ". [PMID: 21221190]
  • P Hadji. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocrine-related cancer. 2008 Mar; 15(1):73-90. doi: 10.1677/erc-07-0193. [PMID: 18310277]
  • Jürgen Geisler. Aromatase inhibitors: from bench to bedside and back. Breast cancer (Tokyo, Japan). 2008; 15(1):17-26. doi: 10.1007/s12282-007-0002-3. [PMID: 18224389]